ClinicalTrials.gg
TerminatedNCT00402298Updated Jun 5, 2025Results posted

Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

A Phase 2 interventional study of Full Dose Midomafetamine HCl and Low Dose Midomafetamine HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Terminated at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was terminated after enrolling five subjects due to staff turnover and its effects on quality of data collection.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
31st of 38
5 · median 25
Started
2007
the only one that year
Phase 2
28 of 38
10 open now
Registered
3rd of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 31st largest by enrollment, is the only one that started in 2007, is one of 28 in phase 2, and was the 3rd registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy can treat PTSD in participants with PTSD. Researchers will compare two sessions of MDMA-assisted therapy with two sessions of low dose (active placebo) MDMA-assisted therapy to determine if MDMA-assisted therapy is safe and works to treat PTSD symptoms.

Participants will be randomly assigned to receive either the full dose of MDMA or low active placebo dose of MDMA during each of two experimental sessions. PTSD symptoms will be measured throughout the study.

Read the detailed description

This study will examine whether two six to eight-hour long sessions of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy scheduled two to four weeks apart are safe, and whether combining a fully therapeutic dose of MDMA with psychotherapy, compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms, with symptoms measured four times, once at baseline and again 2, 6, and 12 months after the second experimental session. People who received the active placebo dose of MDMA can then take part in an "open label" study continuation, with the participant receiving a fully active dose of MDMA on two more six to eight hour-long psychotherapy sessions. Open-label means that the participants and the researchers know that the participant will receive the fully active dose of MDMA. People who take part in the open label study continuation have their PTSD symptoms checked six and 12 months after the second open label MDMA-assisted session.

This study will look at MDMA-assisted therapy in 12 individuals aged 18 years or older, with PTSD symptoms not improving after trying at least one treatment. At least two-thirds of participants will have diagnosed PTSD arising from war or terrorism-related trauma. Eight of 12 participants will be assigned to receive the full dose of MDMA, and four will be assigned to receive a low or "active placebo" dose of MDMA during each of two experimental sessions. The fully active dose consists of an initial dose of 125 mg MDMA HCl and a supplemental dose of 62.5 mg given 2 to 2.5 hours later. The active placebo dose consists of an initial dose of 25 mg MDMA HCl and a supplemental dose of 12.5 mg.

The study will will include two sixty minute long introductory therapy sessions, two active placebo or fully active dose MDMA-assisted therapy sessions, a sixty to ninety minute long therapy session 24 hours after each experimental session, and one to two hour-long therapy sessions occurring weekly between the first and second experimental session, and between the second experimental session and the end of the study.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • PTSD
  • MDMA
  • therapy
  • Posttraumatic stress disorder
  • Israel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Posttraumatic stress disorder still remaining after at least one treatment, with treatment including psychotherapy or pharmacotherapy. At least two-thirds of participants will have PTSD as a result of war and terrorism
  • May meet criteria for a mood disorder.
  • Must be at least 18 years old.
  • Must be able to stop taking psychiatric medication from the start of the study until the two-month follow-up.
  • May continue seeing an outside therapist during the study, but cannot increase the length or frequency of treatments.
  • Must be able to follow all the rules and instructions relating to the experimental session, including restrictions on food and substance (alcohol and drug) consumption
  • Must be willing to stay overnight in the clinic after each experimental session until the non-drug session occurring the next morning.
  • Must be willing to be contacted by one of the researchers on a daily basis for a week after each experimental session.
  • If a woman of , must have a negative pregnancy test and must agree to use an effective form of .
  • Must be able to speak and read Hebrew.

Exclusion criteria

Exclusion Criteria:

  • Cannot have history of or be diagnosed with psychotic disorder or bipolar affective disorder - 1.
  • Cannot be diagnosed with dissociative identity disorder, an eating disorder with active purging, or borderline personality disorder.
  • Cannot have evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder. (People with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
  • Cannot have uncontrolled hypertension, peripheral vascular disease, hepatic disease (with or without abnormal liver enzymes), or history of hyponatremia or hyperthermia.
  • Cannot weigh less than 50 or more than 105 kg.
  • Cannot have used "Ecstasy" more than five times during lifetime or in the past six months.
  • Cannot present a serious suicide risk or be likely to require hospitalization during the course of the study.
  • Cannot require ongoing concomitant therapy with a psychotropic drug.
  • Cannot meet criteria for substance abuse or dependence for any substance save caffeine or nicotine in the past 60 days.
  • Unable to give adequate consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Full dose (125 mg) MDMA-assisted therapy

    Participants will receive an initial dose of 125 mg midomafetamine HCl followed 2.5 hours later by a supplemental dose of 62.5 mg midomafetamine HCl during the course of two day-long therapy sessions.

    Drug: Full Dose Midomafetamine HCl

  • Active comparator
    Active Comparator (25 mg) MDMA-assisted therapy

    Participants will receive an initial dose of 25 mg midomafetamine HCl followed 2.5 hours later by a supplemental dose of 12.5 mg midomafetamine HCl during the course of two day-long therapy sessions.

    Drug: Low Dose Midomafetamine HCl

Interventions

  • Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2.5 hours later by 62.5 mg midomafetamine HCl orally during the course of a day-long therapy session.

    Also known as: midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA HCl, MDMA

  • Participants will receive an initial dose of 25 mg midomafetamine HCl orally followed 2.5 hours later by a supplemental dose of 12.5 mg midomafetamine HCl orally during the course of each of two day-long therapy sessions.

    Also known as: midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA HCl, MDMA

06

What researchers measure

Primary outcomes

  1. Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-Month Follow-Up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to two months after second MDMA-assisted experimental session

Secondary outcomes

  1. Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 6-Month Follow-Up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to six months after second MDMA-assisted experimental session

  2. Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 12-month Follow-up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to twelve months after second MDMA-assisted experimental session

07

Results

Posted Sep 20, 2021
Limitations and caveats
This study was terminated after enrolling five subjects due to staff turnover and its effects on quality of data collection. Limited data were reported to the sponsor and its quality could not be assured and therefore analysis is limited to descriptive statistics of available data.

Participant flow

Participant flow — Overall Study
MilestoneFull Dose (125 mg)Low Dose (25 mg)
Started32
Completed22
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-Month Follow-Up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to two months after second MDMA-assisted experimental session
Reported as:
Mean · units on a scale
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-Month Follow-Up
units on a scaleFull Dose (125 mg) MDMA-assisted TherapyLow Dose (25 mg) MDMA-assisted Therapy
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-Month Follow-Up-0.5 ± 4.95-7 ± 18.38
SecondaryChange in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 6-Month Follow-Up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to six months after second MDMA-assisted experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 6-Month Follow-Up
score on a scaleFull Dose (125 mg) MDMA-assisted TherapyLow Dose (25 mg) MDMA-assisted Therapy
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 6-Month Follow-Up-0.5 ± 6.366
SecondaryChange in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 12-month Follow-up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to twelve months after second MDMA-assisted experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 12-month Follow-up
score on a scaleFull Dose (125 mg)Low Dose (25 mg)
Change in Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 12-month Follow-up-7.5 ± 13.43—

Adverse events

Collected over From informed consent to study termination after 12 month follow up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Dose (125 mg) MDMA-assisted Therapy0/3 (0%)0/3 (0%)2/3 (66.7%)
Low Dose (25 mg) MDMA-assisted Therapy0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventFull Dose (125 mg) MDMA-assisted TherapyLow Dose (25 mg) MDMA-assisted Therapy
FasciculationMusculoskeletal and connective tissue disorders1/31/2
Viral upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/31/2
MyoclonusMusculoskeletal and connective tissue disorders0/31/2
VomitingGastrointestinal disorders1/30/2
FlatulenceGastrointestinal disorders1/30/2

Baseline characteristics

This study was terminated after enrolling five subjects due to staff turnover and its effects on quality of data collection. Limited data was reported to the sponsor and its quality could not be assured. We have updated the record to reflect the limited data received.

Age, Categorical
Age, Categorical(Participants)Full Dose (125 mg)Active Comparator (25 mg)Total
<=18 years000
Between 18 and 65 years224
>=65 years101
Age, Continuous
Age, Continuous(Years)Full Dose (125 mg)Active Comparator (25 mg)Total
Mean45.6 (32 to 66)39 (36 to 42)43 (32 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Full Dose (125 mg)Active Comparator (25 mg)Total
Female000
Male325
Region of Enrollment
Region of Enrollment(participants)Full Dose (125 mg)Active Comparator (25 mg)Total
Israel325
08

Study locations

1 site
  • Be'er Ya'akov Mental Health Center
    Be'er Ya'aqov, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2007 to primary completion in Mar 2009, 22 months.

Results were first posted in Sep 2021, 12 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2006
First posted
Nov 22, 2006
StartActual
May 27, 2007
Primary completionActual
Mar 2009
CompletionActual
May 5, 2010
Results first posted
Sep 20, 2021
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402298
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Nov 22, 2006
Start date
May 27, 2007
Primary completion
Mar 2009
Completion
May 5, 2010
Results posted
Sep 20, 2021
Last update
Jun 5, 2025

Study contacts

Moshe Kotler
principal investigator · Director of Psychiatry, Beer Yaakov Mental Health Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion